Difficulty: Medium
Average Score: 73%
Simulated
A client who suffers from severe persistent allergic asthma is prescribed omalizumab (Xolair). Which statement below correctly describes the mechanism of action associated with omalizumab (Xolair)?
Correct answer
C
Rationale
The correct answer is C. Omalizumab (Xolair) selectively binds to IgE, reducing allergic mediators and asthma attacks. IgE is involved in the allergic response by triggering the release of histamine and other inflammatory mediators. By binding to IgE, omalizumab prevents it from triggering the allergic cascade, thereby reducing asthma attacks.
Choice A is incorrect because omalizumab does not directly inhibit the production of leukotrienes and histamine. Choice B is incorrect as omalizumab does not inhibit mast cells from releasing histamine. Choice D is incorrect as omalizumab does not stimulate alpha-adrenergic receptors.
Choice A is incorrect because omalizumab does not directly inhibit the production of leukotrienes and histamine. Choice B is incorrect as omalizumab does not inhibit mast cells from releasing histamine. Choice D is incorrect as omalizumab does not stimulate alpha-adrenergic receptors.